US-based Eli Lilly yesterday announced the results from the Phase III REACH-2 clinical trial, conducted on patients with liver cancer (HCC) treated with Cyramza (ramucirumab) as a second-line treatment. The trial has delivered positive results and investors have soon rewarded the company, whose shares have risen 2.55%. Eli Lilly is now planning to submit a Marketing Authorization Application before H2 2018. The new indication for Cyramza has potential to generate sales of $960m pa (2021), investors say. Cyramza is already approved for other cancer types–such as stomach and lung cancer–and generated revenues of $204.8m in 2017.
(Source: Yahoo Finance)